Molly Bart, APRN
Primary Care · Tulsa, OKNPI 1700420155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Bioventus LLC at 45.7% of the total. 2025 is the largest year on record at $188, 4.1 times the $46 reported in 2022. That places this record below the midpoint for primary care clinicians in OK, where the typical reported total is $352.
Across 14 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bioventus LLC$164
- AbbVie$50
- Lilly USA, LLC$36
- Johnson & Johnson$32
- Pacira Pharmaceuticals Incorporated$19
- Exact Sciences$16
- plus $43 from 3 others
What the payments were for
- Food & beverage$360100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bioventus LLC | 2 | $164 |
| AbbVie | 3 | $50 |
| Lilly USA, LLC | 2 | $36 |
| Johnson & Johnson(2 entities) | 2 | $32 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Exact Sciences | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Merck | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCELL$150
How this compares
$360 in reported general payments places this provider in the 50th percentile of 83 primary care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 182 | $2,889 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $909 |
| Celecoxib | 19 | $778 |
| Meloxicam | 52 | $326 |
| Methylprednisolone | 47 | $303 |
| Baclofen | 16 | $293 |
| Tamsulosin Hcl | 16 | $286 |
| Cyclobenzaprine Hcl | 54 | $267 |
| Lisinopril | 18 | $232 |
| Atorvastatin Calcium | 17 | $192 |
| Potassium Chloride | 11 | $158 |
Paid to pharmacies, not to this prescriber.
Other primary care in Tulsa
- Cristina SarrosaTulsa$6K
- Stephanie PennieTulsa$3K
- Steven OrtmanTulsa$2K
- Ziva CooperTulsa$460
- Linda WilliamsTulsa$399
- Teri RatzTulsa$300
- Ralynda RozellTulsa$284
- Aimee MusgroveTulsa$235
- Amber MaharSallisaw$9K
- Misty DeanOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.